Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies
| Autor: | Abd El Gawad H Abd El Gawad, Ghada Ahmed El-Emam, Germeen N S Girgis, Mohamed Mohamed Adel El-Sokkary, Osama A. Soliman |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Biophysics
Antifungal drug Pharmaceutical Science Bioengineering 02 engineering and technology 010402 general chemistry 01 natural sciences Biomaterials chemistry.chemical_compound Natamycin Differential scanning calorimetry Drug Discovery Zeta potential medicine Fungal keratitis Voriconazole Chromatography Organic Chemistry General Medicine Poloxamer 021001 nanoscience & nanotechnology medicine.disease 0104 chemical sciences chemistry Methyl cellulose 0210 nano-technology medicine.drug |
| Zdroj: | International Journal of Nanomedicine. 15:7825-7840 |
| ISSN: | 1178-2013 |
| DOI: | 10.2147/ijn.s268208 |
| Popis: | Background Voriconazole (VRC) is a triazole broad spectrum antifungal drug, used in the management of versatile fungal infections, particularly fungal keratitis. The obligatory use of niosomal delivery of VRC may reduce the frequency of dosing intervals resulting from its short biological half time and consequently improve patient compliance. Methods VRC loaded proniosomes (VRC-PNs) were set by the coacervation technique and completely characterized. The developed formula was comprehensively assessed concerning in- vitro release behavior, kinetic investigation, and its conflict against refrigerated and room temperature conditions. A selected noisomal formula was incorporated into ocusert (VRC-PNs Ocu) formulated by 1% w/w hydroxypropyl methyl cellulose HPMC and 0.1% w/w carbopol 940. Eventually, in vitro antifungal activity against Candida albicans and Aspergillus nidulans was assessed by the cup diffusion method. Results The optimized VRC-PNs (Pluronic F127: cholesterol weight ratio 1:1 w/w) exhibited the highest entrapment efficiency (87.4±2.55%) with a spherical shape, proper size in nano range and a suitable Zeta potential of 209.7±8.13 nm and -33.5±1.85 mV, respectively. Assurance of drug encapsulation in nanovesicles was accomplished by several means such as attenuated total reflection Fourier-transform infrared spectroscopy, differential scanning calorimetry in addition to powder X-ray diffraction investigations. It displayed a biphasic in vitro release pattern and after 6 months of storage at a refrigerated temperature, the optimized formula preserved its stability. VRC-PNs Ocu proved a very highly significant antifungal activity matched with the free drug or nanosuspension which was extra assured by comparing its mean inhibition zone with that of 5% natamycin market eye drops. Conclusion In conclusion, VRC-PNs Ocu could be considered as a promising stable sustained release topical ocular nanoparticulate system for the management of fungal infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|